La Grange, Ill. (January 30, 2006) – Tonalin® CLA (conjugated linoleic acid) research was selected by internationally recognized journal editors and scientific reviewers as one of 25 “exemplary” papers to appear in the National Institutes of Health (NIH) Office of Dietary Supplements’ (ODS) Annual Bibliography of Significant Advances in Dietary Supplement Research 2004 (http://ods.od.nih.gov/pubs/ODS_CHPA_Bibliography_2004.pdf).
More than 325 original research articles from 53 peer-reviewed journals were nominated for inclusion in the ODS review. An international team of 49 expert reviewers ranked the articles and the top 25 were selected for the Bibliography which was released in October 2005. The research is intended “to provide health practitioners and consumers with the necessary information to help them assess the contributions that dietary supplements make to nutrient intakes and health,” according to an NIH news release.
“This recognition from the world’s foremost scientific authorities is an amazing testament to the research that continues to distinguish Tonalin® as the leading brand of CLA for optimal body composition,” said Christine Peggau, Global Market Segment Manager, Cognis Nutrition & Health. “It is an honor to be included in this prestigious publication and we congratulate Dr. Jean-Michel Gaullier, of Scandinavian Clinical Research in Kjeller, Norway, and his colleagues for their outstanding work.” Duane Fimreite, Cognis’ Global Tonalin® CLA Product Manager, added that this recognition of CLA's benefits further strengthens Cognis’ strategy to globally position Tonalin® CLA as an important nutritional ingredient in weight management and related fields for both supplements and functional foods.
The CLA paper was the first study to document the long-term safety and efficacy of Tonalin® CLA supplementation and was published the American Journal of Clinical Nutrition (Gaullier J-M. et al., Am. J. Clin. Nutr., 2004; 79(6):1118-1125). Researchers found that Tonalin® CLA, an exclusive product of the Cognis Group, reduces body fat mass in overweight, but otherwise healthy, adults by as much as nine percent. The randomized, double blind, placebo-controlled study was conducted over a 12-month period without additional lifestyle or dietary restrictions.
"The results of this first long-term study indicate that CLA, taken for one year as a dietary supplement, safely improves the ratio of body fat to lean tissue in overweight, but otherwise healthy, adults," said Dr. Gaullier.
A continuation of this landmark study published in the April, 2005 Journal of Nutrition (Gaullier, J-M et al, J. Nutr., 2005;135:778-784) concludes that long-term supplementation with Tonalin® CLA is safe and well-tolerated. Furthermore, the two-year study confirms that taking CLA decreases body fat mass and maintains lean body mass, reducing the potential ‘yo yo’ effect often associated with diet plans.
Dr. Gaullier explained that this follow-up study “helped study participants keep off lost weight while maintaining lean body mass – which keeps the metabolism going strong and burning calories, thereby reducing the chances of weight regain.” The results of Dr. Gaullier’s research corroborate and expand upon earlier findings demonstrating that CLA could be a valuable addition to a healthy diet and exercise program for weight management.